Updates in Chronic Lymphocytic Leukemia from ASH 2018

1 Views

07/08/23

Matthew Davids, MD, MMSc, associate director of the Chronic Lymphocytic Leukemia Center at Dana-Farber, shares exciting advances in CLL treatment from the 2018 ASH Annual Meeting. Highlights include practice-changing studies using ibrutinib in the frontline setting, as well as opportunities to combine venetoclax with other treatments. Learn more about the Center for Lymphocytic Leukemia: https://www.dana-farber.org/ce....nter-for-chronic-lym